SIGA Technologies, Inc.  

(Public, OTCMKTS:SIGAQ)   Watch this stock  
Find more results for NASDAQ:SIGA
-0.050 (-11.09%)
Feb 11 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.40 - 0.45
52 week 0.20 - 2.68
Open 0.44
Vol / Avg. 7,890.00/79,594.00
Mkt cap 21.65M
P/E     -
Div/yield     -
EPS -0.72
Shares 54.11M
Beta 1.79
Inst. own 14%

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -424.18% -8454.67%
Operating margin -420.15% -6745.36%
EBITD margin - -664.06%
Return on average assets -11.90% -147.39%
Return on average equity - -
Employees 34 -
CDP Score - -


660 Madison Ave Ste 1700
NEW YORK, NY 10065-8446
United States - Map
+1-212-6729100 (Phone)
+1-212-6973130 (Fax)

Website links


SIGA Technologies, Inc. (SIGA) is a pharmaceutical company. The Company is engaged in the development and commercialization of solutions for serious unmet medical needs and biothreats. The Company's lead product is Tecovirimat, also known as ST-246, an orally administered antiviral drug that targets orthopoxviruses, including smallpox. Tecovirimat is not licensed as safe or effective by the U.S. Food & Drug Administration (USFDA), it is a small-molecule drug that is being delivered to the Strategic National Stockpile under Project BioShield. For the manufacture of Tecovirimat, the Company uses the following contract manufacturing organizations: Albemarle Corporation (Albemarle), Powdersize, Inc. (Powdersize) and Catalent Pharma Solutions LLC (Catalent).

Officers and directors

Eric A. Rose M.D. Chairman of the Board, Chief Executive Officer
Age: 64
Daniel J. Luckshire Chief Financial Officer, Executive Vice President, Secretary
Age: 44
Dennis E. Hruby Ph.D. Chief Scientific Officer, Vice President
Age: 63
James J. Antal CPA Independent Director
Age: 64
Michael Jonathan Bayer Independent Director
Age: 66
Thomas E. Constance Independent Director
Age: 79
Jeffrey B. Kindler Independent Director
Age: 60
Joseph W. Marshall III Independent Director
Age: 62